BRAF Biomarkers
Black Diamond Therapeutics to Discontinue ErbB Inhibitor Program, Lay Off 30 Percent of Workforce
The company is shifting its focus to developing EGFR and BRAF inhibitors and believes cutting staff will extend its cash runway into Q3 2024.
Multiple successor trials are in the works based on hits, misses, and overall knowledge gained from one of the first precision medicine platform trials.
NCI-MATCH Umbrella Trial Adds Arm for LAG-3 Expressing, Mismatch Repair Deficient Cancers
Researchers said that patients in the new arm will receive BMS'Â Opdivo and relatlimab, and that the trial will also expand an existing arm for BRAF-mutated cancers.
Erasca, Eli Lilly Partner to Study ERAS-007, Erbitux in BRAF V600E-Mutant Colorectal Cancer
Lilly will supply Erbitux at no cost for the ongoing Phase Ib/II HERKULES-3 trial, in which Erasca is studying its ERK inhibitor with other approved drugs.Â
Seattle Cancer Care Alliance Aims to Improve Molecular Profiling Access for Thyroid Cancer Patients
Premium
The project is focused on building a workflow to improve guideline-concordant molecular testing, which researchers hope will reduce insurance denials and improve community access.